There is research on this stock available only to PRO subscribers.
There are no Related articles on CONX.
There are no Transcripts on CONX.
Thu, Aug. 28, 9:15 AM| Comment!
Mon, Aug. 11, 3:59 PM
- Corgenix (OTCQB:CONX -13.3%) begins work on a rapid diagnostic test for Ebola. The company is working with the Viral Hemorrhagic Fever Consortium (VHFC) under a three-year NIH grant to develop a test kit.
- Corgenix CEO Douglass Simpson warns against unrealistic expectations regarding the current outbreak by saying, "I want to strongly emphasize that this (NIH grant) is a new three-year project, building off work commenced in 2010. We do not currently have an Ebola test nor will we likely have a final one in the near future. We understand the critical nature of this virus and are doing everything possible to accelerate efforts to develop reliable and rapid result diagnostic kits in order to be ready for the next outbreak."
Mon, Jul. 14, 10:39 AM
- Corgenix Medical Corp. (CONX +1.3%) signs a technology transfer and product development agreement with Mellitus LLC for an in vitro diagnostic test for Glycated CD59, a marker with potential utility in screening, diagnosing and monitoring diabetes. Under the terms of the agreement, Corgenix will develop a test kit to measure CD59 for Mellitus' U.S. and European Union commercialization programs.
CONX vs. ETF Alternatives
Other News & PR